Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

To evaluate the clinical effects of switching from premixed human insulin to a premixed rapid-acting insulin analogue in type 2 diabetic patients.

Who Took Part

According to the abstract, 2 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults.

Insulin therapy-related quality of life (ITR-QOL) and the diabetes treatment satisfaction questionnaire (DTSQ) were also assessed in the analogue mix group at the beginning of the study and again 4 months later.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

At the beginning of the study, and again 4 months later, HbA1c and blood glucose levels were measured, and the amount of insulin required and BMI were recorded in both groups.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Insulin, Insulin Lispro and Quality of Life.

What This Means in Plain Language

The paper is a randomized study of Insulin Lispro in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Internal medicine (Tokyo, Japan)), a journal based in Japan.

More context: the Insulin Lispro compound page, all human trials.